QRxPharma abandons MoxDuo development
15 August, 2014 by Dylan Bushell-EmblingQRxPharma (ASX:QRX) has ceased development of dual-opioid drug MoxDuo, after the board decided that the cost of additional trials sure to be required for US approval could not be justified.
Industry leaders propose AIM Incentive to boost innovation
14 August, 2014Australian industry leaders have proposed an Australian Innovation & Manufacturing (AIM) Incentive in submissions to the Senate's inquiry into Australia's innovation system.
Perth's Orthocell lists on ASX
13 August, 2014 by Dylan Bushell-EmblingOrthocell (ASX:OCC) has listed on the ASX following last month's $8m IPO and started receiving royalty revenue from China for regenerative medicine product Ortho-ACI.
CSL's FY14 profit grows 8% to $1.4bn
13 August, 2014 by Dylan Bushell-EmblingCSL (ASX:CSL) has reported an 8% growth in FY14 profit, despite the impact of a legal settlement and a decline in sales at its bioCSL division.
Bespoke biotech
13 August, 2014 by Tim DeanAdditive manufacturing and 3D printing technology have a lot to offer makers of biomedical devices.
International bio-industry associations join to comment on the USPTO's subject matter eligibility guidance
12 August, 2014 by Anna LavelleBiotech industry associations join forces to express concerns about changes to US non-statutory patent law.
GI Dynamics recruiting for EndoBarrier utility trial
11 August, 2014 by Dylan Bushell-EmblingGI Dynamics (ASX:GID) has signed on the first obese patients for a utility trial of EndoBarrier in France and reported year-on-year revenue growth but a wider net loss for Q1.
Phosphagenics completes IND-enabling pain patch study
11 August, 2014 by Dylan Bushell-EmblingPhosphagenics (ASX:POH) achieved encouraging results from the first of two planned IND-enabling phase I trials of pain patch TPM/oxymorphone.
Clinuvel rejects $95m takeover offer
08 August, 2014 by Dylan Bushell-EmblingClinuvel (ASX:CUV) has declined a takeover bid from US-based Retrophin, with the board electing to focus the company's efforts on pursuing EMA approval for Scenesse in skin condition EPP.
Mesoblast MPCs to be trialled in end-stage heart failure
08 August, 2014 by Dylan Bushell-EmblingMesoblast and the US National Institutes of Health will team up for a 120-patient trial of the company's MPCs in end-stage heart failure.
AusBiotech submits to Senate Inquiry into Australia's Innovation System
07 August, 2014AusBiotech's substantive submission to the Senate Standing Committee on Economics' Australian Innovation System inquiry has called for tax reform, support for commercialisation, incentives for commercial thinking and clinical trial reform.
Immuron's Travelan launches in Canada
06 August, 2014 by Dylan Bushell-EmblingImmuron's (ASX:IMC) distribution partner Paladin Labs has launched OTC travellers' diarrhoea treatment Travelan in Canada.
AOD9604 awarded safe status in US
06 August, 2014 by Dylan Bushell-EmblingCalzada (ASX:CZD) said its peptide AOD9604 has secured Generally Recognised As Safe status in the US, allowing its use in food and supplements at a daily level of up to 1 mg per person.
Nominate Australia's biotech leaders for this year's Industry Excellence Awards
05 August, 2014Who do you think are the industry's high achievers? The annual Industry Excellence Awards celebrate the individuals and organisations that have made a significant contribution to the biotechnology industry and, through their leadership, continue to make a difference to the growth of the bio-economy. The recipients of these prestigious awards are at the forefront of thriving biotech, innovation and healthcare sectors in Australia.
ResMed Q4 net grows 20% despite weak Americas sales
05 August, 2014 by Dylan Bushell-EmblingResMed (ASX:RMD) has reported a 20% growth in profit but flat revenue for the fourth quarter, and reported the results of a successful study into using NPPH to treat advanced COPD.
